Preliminary research on colorectal cancer neoadjuvant therapy sensitivity through high-throughput transcriptome sequence

doi:10.16139/j.1007-9610.2018.01.015

Abstract

Abstract: Objective To screen and identify the genes associated with sensitivity of neoadjuvant therapy for the patients with colorectal cancer through high-throughput transcriptome sequence technology and bioinformatics tools by analysis of the genes which expressed differently. Methods RNA was extracted from the tumor tissue of 22 patients with co-lorectal cancer who received standard neoadjuvant therapy before operation. Nine cases were divided as sensitive group and 11 cases as non-sensitive group based on tumor regression grading. Strand libraries were constructed for high-throughput sequencing. The genes filtered the false discovery rate(<0.05) were mapped to the reference genome, and assembled. The obtained transcripts were classified and annotated and the characteristics of gene were analyzed. Results The gene database associated with neoadjuvant therapy for colorectal cancer was built preliminarily. From 22 patients with colorectal cancer tissues, 89 genes were found up-regulated significantly and 112 genes down-regulated. Conclusions The genes related to the sensitivity of colorectal cancer neoadjuvant therapy were identified in this study using high-throughput transcriptome sequence.

Key words: Colorectal Cancer, Neoadjuvant therapy, Therapy sensitivity, Transcriptome sequencing

CLC Number:

CHEN Xianze, CHENG Xi, WU Haoxuan, ZHANG Tao, JI Xiaopin, ZHAO Ren. Preliminary research on colorectal cancer neoadjuvant therapy sensitivity through high-throughput transcriptome sequence[J]. Journal of Surgery Concepts & Practice, 2018, 23(01): 67-71.

References

[1] 赵任, 蒋奕玫. 直肠癌外科手术治疗进展[J]. 外科理论与实践,2016,16(6):468-471.
[2] Kuebler JP, Wieand HS, O′Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage Ⅱ and Ⅲ colon cancer: results from NSABP C-07[J]. J Clin Oncol,2007,25(16):2198-2204.
[3] Haller DG, Tabernero J, Maroun J, et al.Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stageⅢ colon cancer[J]. J Clin Oncol,2011,29(11):1465-1471.
[4] McGee MF, Benson AB 3rd. Adjuvant chemotherapy for stageⅡ colon cancer: everyone still needs a tailor[J]. Ann Surg Oncol,2014,21(16):1765-1767.
[5] Teufel A, Gerken M, Hartl J, et al.Benefit of adjuvant chemotherapy in patients with T4 UICC Ⅱ colon cancer[J]. BMC Cancer,2015,15(8):419.
[6] Gunderson LL, Jessup JM, Sargent DJ, et al.Revised TN categorization for colon cancer based on national survival outcomes data[J]. J Clin Oncol,2010,28(2):264-271.
[7] 顾晋, 陈鹏举. 胃肠外科医师应重视结直肠癌的辅助化疗[J]. 中华胃肠外科杂志,2015,18(10):974-978.
[8] 孙艳武, 池畔, 徐本华, 等. 直肠癌新辅助放化疗后病理完全缓解预测因素分析[J]. 中华胃肠外科杂志,2014,17(6):556-560.
[9] Kapranov P, Cheng J, Dike S, et al.RNA maps reveal new RNA classes and a possible function for pervasive transcription[J]. Science,2007,316(5830):1484-1488.
[10] 孙凯, 黄晓卉, 甄茂川, 等. 应用液相芯片分析肝细胞癌及癌旁组织小分子RNA表达谱差异[J]. 中华实验外科杂志,2006,23(8):945-947.
[11] 李智勇, 林维文, 官国先, 等. 新辅助放化疗对mrT3期低位直肠癌患者不同浸润深度远期疗效的影响[J]. 中国肿瘤临床,2015,13(5):377-379.
[12] 戴朝六, 徐峰. 个体化治疗直肠癌同时性肝转移[J]. 中华消化外科杂志,2014,13(3):175-179.
[13] Maas M, Nelemans PJ, Valentini V, et al.Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection a pooled analysis of 3,313 patients[J]. Int J Cancer,2015,137(1):212-220.
[14] Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group[J]. J Clin Oncol,2007,25(28):4379-4386.
[15] Hong YS, Nam BH, Kim KP, et al.Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leuco-vorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy(ADORE): an open-label, multicentre, phase 2, randomised controlled trial[J]. Lancet Oncol,2014,15(11):1245-1253.
[16] Zorcolo L, Rosman AS, Restivo A, et al.Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis[J]. Ann Surg Oncol,2012,19(9):2822-2832.
[17] Bujko K, Glynne-Jones R, Bujko M.Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials[J]. Ann Oncol,2010,21(9):1743-1750.
[18] Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses[J]. J Clin Oncol,2011,29(28):3768-3774.
[19] Colas E, Muinelo-Romay L, Alonso-Alconada L, et al.ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas[J]. Oncogene,2012,31(45):4778-4788.
[20] Bao Y, Peng W, Verbitsky A, et al.Human coxsackie adenovirus receptor(CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes[J]. Prostate,2005,64(4):401-407.